Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Kamada ( (IL:KMDA) ).
Kamada Ltd. announced the enrollment of the first patient in a clinical trial for CYTOGAM®, aimed at preventing late Cytomegalovirus (CMV) infection in kidney transplant recipients. This study, known as SHIELD, seeks to address the unmet medical need for reducing late CMV disease risk in high-risk transplant patients, potentially improving outcomes. The trial is supported by Kamada and led by experts in transplant-related infections, highlighting the company’s commitment to the transplant community and its strategic focus on innovative prophylactic approaches.
The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs2519.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies. The company offers a portfolio of marketed products for rare and serious conditions, including six FDA-approved specialty plasma-derived products. Kamada focuses on organic growth through commercialization, business development, expansion of plasma collection operations, and advancing product candidates targeting unmet medical needs.
Average Trading Volume: 51,075
Technical Sentiment Signal: Buy
Current Market Cap: ILs1.31B
See more insights into KMDA stock on TipRanks’ Stock Analysis page.